Time to ‘Tune-up’ your Supply Chain

This month my focus is on Supply Chain in Life Sciences. As we head towards the end of the year budgets are being planned and IT projects are being prioritized for next year. Many companies are reviewing their current IT investments in light of mergers and acquisitions and projects that will add to the company’s Read More

Drug shortages will impact Healthcare…

Most of us are excited about the changes occurring in healthcare around mobile applications, electronic health records and the advent of social media just to name a few examples. Yet there is a mounting concern with the rise of drug shortages now reported at “178 a 3x rise since 2005!” A look at the FDA web site Read More

Aligning Life Sciences and Healthcare IT. Part 2 A Practical Mobility Solution for Doctors and Nurses.

In a previous blog post I introduced the ‘value chain’ for these industries, and discussed lessons learned from Life Sciences IT to help Healthcare IT in the use of technology. In Part 2 I am providing a practical application on the use of handheld (mobile) devices being used by doctors and nurses for ‘intimate healthcare.’ At the end of this article I will provide a link to this ‘case study’ which we have named Patient Monitoring System (PMS).

Aligning Life Sciences and Healthcare IT. Can IT bridge the gap? Part1

What lessons can Healthcare Information Technology (IT) take from the Life Sciences IT? My background has been in Life Sciences and looking into Healthcare I can’t help but notice the similarities and differences in the use of technology. So how do we ‘evolve’ from our current position to fulfill this new ‘model’ of healthcare? In this posting I will focus on the Life Sciences portion of the value chain.

New Research Model to Accelerate Drug Development

Online Webinar (25March2010) on “Developing Cures with Less Time and Capital” discusses a new research model for drug development. With the focus on healthcare costs, what can be done to improve success in developing new treatments? How can this model help the pharmaceutical industry gain a greater ROI around drug development?